Stay updated with breaking news from Bio Partners. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pharvaris (NASDAQ:PHVS – Get Free Report)‘s stock had its “overweight” rating reiterated by investment analysts at Morgan Stanley in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $34.00 price target on the stock. Morgan Stanley’s price objective indicates a potential upside of 64.65% from the stock’s previous […]
Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report) reached a new 52-week low during trading on Wednesday . The company traded as low as $5.61 and last traded at $5.67, with a volume of 81890 shares changing hands. The stock had previously closed at $5.95. Wall Street Analysts Forecast Growth A number of research analysts have […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Free Report) – Investment analysts at HC Wainwright upped their Q1 2024 EPS estimates for Elevation Oncology in a research report issued to clients and investors on Thursday, March 7th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.20) per share for the quarter, up from […]
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants Upfront net proceeds to provide funds to conduct clinical development of cytisinicline through New Drug Application submission...
Acelyrin, Inc. (NASDAQ:SLRN – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 12-month price objective among […]